Literature DB >> 30950060

Identification of lncRNA-miRNA-mRNA regulatory network associated with epithelial ovarian cancer cisplatin-resistant.

Xin Zhao1, Dong-Yang Tang2, Xu Zuo1, Tian-Dong Zhang1, Cheng Wang3.   

Abstract

To construct a long noncoding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) regulatory network related to epithelial ovarian cancer (EOC) cisplatin-resistant, differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs), and differentially expressed miRNAs (DEMs) between MDAH and TOV-112D cells lines were identified. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to analyze the biological functions of DEGs. Downstream mRNAs or upstream lncRNAs for miRNAs were analyzed at miRTarBase 7.0 or DIANA-LncBase V2, respectively. A total of 485 significant DEGs, 85 DELs, and 5 DEMs were identified. Protein-protein interaction (PPI) network of DEGs contrains 81 nodes and 141 edges was constructed, and 25 hub genes related to EOC cisplatin-resistant were identified. Subsequently, a lncRNA-miRNA-mRNA regulatory network contains 4 lncRNAs, 4 miRNAs, and 35 mRNAs was established. Taken together, our study provided evidence concerning the alteration genes involved in EOC cisplatin-resistant, which will help to unravel the mechanisms underlying drug resistant.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cisplatin-resistant; epithelial ovarian cancer; lncRNA; mRNA; miRNA

Mesh:

Substances:

Year:  2019        PMID: 30950060     DOI: 10.1002/jcp.28587

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  19 in total

1.  Upregulated lncRNA CASC9 Contributes to Progression of Non-Small Cell Lung Cancer Through Inhibition of miR-335-3p and Activation S100A14 Expression.

Authors:  Weigang Zhao; Tangbing Chen; Yonghong Zhao
Journal:  Onco Targets Ther       Date:  2020-06-24       Impact factor: 4.147

2.  A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets.

Authors:  Yepeng Li; Shiqing Huang; Zhongheng Wei; Bo Yang
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

Review 3.  The Emerging Role of Major Regulatory RNAs in Cancer Control.

Authors:  Xiaofeng Dai; Aman Chandra Kaushik; Jianying Zhang
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

4.  LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis.

Authors:  Juan Zhao; Ting Yang; Long Li
Journal:  Onco Targets Ther       Date:  2020-03-19       Impact factor: 4.147

5.  Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy.

Authors:  Jinyuan He; Chulian Gong; Jie Qin; Mingan Li; Shaohong Huang
Journal:  Nanoscale Res Lett       Date:  2019-11-08       Impact factor: 4.703

6.  Aberrantly expressed long non-coding RNAs in air pollution-induced congenital defects.

Authors:  Zheng Li; Jianqing Ma; Xingye Li; Matthew T V Chan; William K K Wu; Zhanyong Wu; Jianxiong Shen
Journal:  J Cell Mol Med       Date:  2019-09-26       Impact factor: 5.310

7.  lncRNA HAND2-AS1 Regulates Prostate Cancer Cell Growth Through Targeting the miR-106a-5p/RBM24 Axis.

Authors:  Pengtao Wei; Jing Yang; Dandan Zhang; Meng Cui; Lianjun Li
Journal:  Onco Targets Ther       Date:  2020-05-21       Impact factor: 4.147

8.  KCNQ1OT1 promotes ovarian cancer progression via modulating MIR-142-5p/CAPN10 axis.

Authors:  Hongli Liu; Ruixin Chen; Fenhong Kang; Haiqing Lai; Yanlong Wang
Journal:  Mol Genet Genomic Med       Date:  2020-01-07       Impact factor: 2.183

Review 9.  Probing lncRNA-Protein Interactions: Data Repositories, Models, and Algorithms.

Authors:  Lihong Peng; Fuxing Liu; Jialiang Yang; Xiaojun Liu; Yajie Meng; Xiaojun Deng; Cheng Peng; Geng Tian; Liqian Zhou
Journal:  Front Genet       Date:  2020-01-31       Impact factor: 4.599

10.  lncRNA FOXD2-AS1 promotes hemangioma progression through the miR-324-3p/PDRG1 pathway.

Authors:  Tiancheng Zhao; Jiayu Zhang; Cong Ye; Leilei Tian; Yezhou Li
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.